Although ROBO2 inhibitors could be a promising therapeutic strategy for treatment of pulmonary hypoplasia related to CDH, more studies are necessary to carefully evaluate the differentiated capacity of these epithelial progenitor cells in the in vivo CDH context and the potential improvement in both lung morphological defects and neonatal respiratory function. This evidence concerns the gene ROBO2 and Pulmonary hypoplasia.